Fox Run Management’s 2seventy bio TSVT Stock Holding History

Fox Run Management’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,754	Closed	-$138K	–	933
2022 Q4	$138K	Buy	+14,754	New	+$208K	0.06%	538

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fox Run Management's TSVT Position: Q1 2023 in Review

Fox Run Management sold out of 2seventy bio (TSVT) in Q1 2023, closing a stake of 14,754 shares — an estimated $138K sold.

Fox Run Management first reported a position in TSVT in Q4 2022 and held it in 1 quarter. The position peaked at $138K in Q4 2022. 146 funds tracked by Wall St. Rank hold TSVT as of Q1 2023.

Fox Run Management reported no remaining 2seventy bio position as of Q1 2023 after selling out during the quarter.
Fox Run Management sold 14,754 2seventy bio shares in Q1 2023, an estimated $138K.
Fox Run Management first reported a position in 2seventy bio in Q4 2022 and held it in 1 quarter.
Fox Run Management's 2seventy bio position peaked at $138K in Q4 2022.
146 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.